Skip to main content

Table 3 Blood creatine kinase (CK), urinary 3-methylhistidine (3MH), C-reactive protein (CRP), cortisol, free and total testosterone, and perceived recovery score (PRS) in participants performing a 12 week weight training regimen and supplemented with either a placebo or ATP. a

From: Effects of oral adenosine-5′-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men

  

Week of Study

 
 

0

1

4

8

9

10

12

p-valueb

CK, IU/L

        

Placebo

141 ± 12

582 ± 77

373 ± 13

246 ± 29

484 ± 52

528 ± 72

187 ± 21

 

ATP

145 ± 8

500 ± 71

324 ± 14

234 ± 32

426 ± 44

449 ± 62

160 ± 20

0.91

24 h 3MH:Cr, μmol:mg

       

Placebo

0.127 ± 0.007

0.130 ± 0.003

Nmc

0.123 ± 0.004

0.134 ± 0.005

0.152 ± 0.005

Nm

 

ATP

0.136 ± 0.008

0.127 ± 0.007

Nm

0.143 ± 0.007#

0.143 ± 0.008

0.131 ± 0.012#

Nm

0.007

CRP, mg/L

        

Placebo

1.9 ± 0.7

1.1 ± 0.1

1.3 ± 0.3

2.0 ± 0.7

1.6 ± 0.7

1.2 ± 0.2

1.6 ± 0.4

 

ATP

1.4 ± 0.4

1.1 ± 0.1

1.2 ± 0.2

1.9 ± 0.6

1.7 ± 0.6

1.1 ± 0.1

1.2 ± 0.2

0.99

Cortisol, μg/dL

        

Placebo

19.7 ± 1.1

20.8 ± 1.3

19.0 ± 1.2

19.2 ± 0.4

22.0 ± 0.4

23.6 ± 0.3

20.3 ± 0.6

 

ATP

20.9 ± 1.2

20.5 ± 1.3

18.4 ± 1.4

19.0 ± 0.4

21.5 ± 0.4

22.6 ± 0.2

19.7 ± 0.6

0.86

Free Testosterone, ng/dL

        

Placebo

103 ± 13

112 ± 10

119 ± 6

111 ± 9

98 ± 6

100 ± 9

113 ± 12

 

ATP

112 ± 13

114 ± 9

118 ± 6

117 ± 11

108 ± 7

110 ± 10

125 ± 13

0.93

Total Testosterone, ng/dL

        

Placebo

591 ± 73

620 ± 58

625 ± 55

585 ± 58

551 ± 46

536 ± 88

605 ± 72

 

ATP

660 ± 67

645 ± 54

695 ± 60

645 ± 60

621 ± 49

592 ± 84

673 ± 69

0.83

PRSd

        

Placebo

9.1 ± 0.3

4.7 ± 0.4

7.0 ± 0.3

7.6 ± 0.2

4.8 ± 0.3

4.4 ± 0.3

7.6 ± 0.2

 

ATP

9.6 ± 0.2

4.9 ± 0.4

7.5 ± 0.3

8.2 ± 0.3

5.5 ± 0.4

5.5 ± 0.4

8.6 ± 0.4

0.61

  1. aMean ± SEM for n = 11 ATP (400 mg ATP/d taken 30 min prior to exercise) and n = 10 placebo supplemented participants.
  2. bProbability of treatment by time difference between the placebo and the ATP treatments over the 12-week study. The mixed model in SAS® was used with the main effects of treatment, week and treatment by week, with the value for week 0 used as a covariate. The mixed model in SAS® was also used for 3MH:Cr: however, 3MH:Cr was measured only at weeks 0, 1, 8, 9, and 10. The model used these values with week 0 as a covariate for determining the overall treatment by time effect for 3MH:Cr.
  3. cNot measured.
  4. dPerceived recovery score is rated on the participants feeling of recovery from the last workout on a scale of 0-10. 0-2 indicates poor recovery and an anticipated decline in performance; 4-6 indicates low to moderate recovery and expected similar performance; and 8-10 indicates highly perceived recovery and expected increases in performance.
  5. #Significantly different than corresponding placebo, t-test (p < 0.05).